Rubius Therapeutics, Inc. (RUBY)
Chart Events
Performance Outlook
| Previous Close | 10.38 |
| Open | 10.35 |
| Bid | 9.58 x 1300 |
| Ask | 9.67 x 1000 |
| Day's Range | 9.50 - 10.53 |
| 52 Week Range | 3.35 - 15.99 |
| Volume | 327,746 |
| Avg. Volume | 1,457,421 |
| Market Cap | 790.226M |
| Beta (5Y Monthly) | 2.22 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.08 |
| Earnings Date | Feb 23, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.90 |
Fair Value
Related Research
- Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover
- Analyst Report: Gilead Sciences, Inc.
- GlobeNewswire
Rubius Therapeutics to Participate in the 10th Annual SVB Leerink Global Healthcare Conference
CAMBRIDGE, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced that Pablo J. Cagnoni, M.D., president and chief executive officer, and the executive management team will participate in a fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference on February 25, 2021, at 11:20 a.m. EST. A live audio webcast will be available within the Investors & Media section of the Rubius Therapeutics website. An archived replay will be accessible for 90 days following the event. About Rubius Therapeutics Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics™. The Company’s proprietary RED PLATFORM® was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and off-the-shelf allogeneic cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Rubius’ initial focus is to advance RCT™ product candidates for the treatment of cancer and autoimmune diseases by leveraging two distinct therapeutic modalities — potent cell-cell interaction and tolerance induction. Rubius Therapeutics was recently named among the Top Places to Work in Massachusetts by the Boston Globe, and its manufacturing site was recently named 2020 Top 5 Best Places to Work in Rhode Island among medium-sized companies by Providence Business News. For more information, visit www.rubiustx.com, follow us on Twitter or LinkedIn or like us on Facebook. Contacts: InvestorsElhan Webb, CFA, VP Investor Relationselhan.webb@rubiustx.com Media Marissa Hanify, Director, Corporate Communicationsmarissa.hanify@rubiustx.com Dan Budwick, 1AB+1 (973) 271-6085dan@1abmedia.com
- GlobeNewswire
Rubius Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results
CAMBRIDGE, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is using its platform to genetically engineer red blood cells into medicines, called Red Cell Therapeutics™, for the treatment of cancer and autoimmune diseases, today announced plans to report fourth quarter and full year 2020 financial results on Tuesday, February 23, 2021, before market open. The company will not be hosting a teleconference in conjunction with its financial results press release. About Rubius TherapeuticsRubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics™. The Company’s proprietary RED PLATFORM® was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and off-the-shelf allogeneic cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Rubius’ initial focus is to advance RCT™ product candidates for the treatment of cancer and autoimmune diseases by leveraging two distinct therapeutic modalities — potent cell-cell interaction and tolerance induction. Rubius Therapeutics’ manufacturing site was recently named 2020 Top 5 Best Places to Work in Rhode Island among medium-sized companies by Providence Business News. For more information, visit www.rubiustx.com, follow us on Twitter or LinkedIn or like us on Facebook. Contacts:Elhan Webb, CFAVice President, Investor Relationselhan.webb@rubiustx.comMedia: Marissa HanifyDirector, Corporate Communicationsmarissa.hanify@rubiustx.com Dan Budwick1AB +1 (973) 271-6085dan@1abmedia.com
- GlobeNewswire
Rubius Therapeutics to Participate in Guggenheim Healthcare Talks | 2021 Oncology Days
CAMBRIDGE, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced that Pablo J. Cagnoni, M.D., president and chief executive officer, and the executive management team will participate in a fireside chat at the Guggenheim Healthcare Talks | 2021 Oncology Days on February 11, 2021, at 2:30 p.m. EST. A live audio webcast will be available within the Investors & Media section of the Rubius Therapeutics website. An archived replay will be accessible for 90 days following the event. About Rubius Therapeutics Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics™. The Company’s proprietary RED PLATFORM® was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and off-the-shelf allogeneic cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Rubius’ initial focus is to advance RCT™ product candidates for the treatment of cancer and autoimmune diseases by leveraging two distinct therapeutic modalities — potent cell-cell interaction and tolerance induction. Rubius Therapeutics was recently named among the Top Places to Work in Massachusetts by the Boston Globe, and its manufacturing site was recently named 2020 Top 5 Best Places to Work in Rhode Island among medium-sized companies by Providence Business News. For more information, visit www.rubiustx.com, follow us on Twitter or LinkedIn or like us on Facebook. Contacts: InvestorsElhan Webb, CFA, VP Investor Relationselhan.webb@rubiustx.com Media Marissa Hanify, Director, Corporate CommunicationsMarissa.hanify@rubiustx.com Dan Budwick, 1AB+1 (973) 271-6085dan@1abmedia.com
